Potent HIV-1 protease inhibitors incorporating meso-bicyclic urethanes as P2-ligands: structure-based design, synthesis, biological evaluation and protein–ligand X-ray studies
作者:Arun K. Ghosh、Sandra Gemma、Jun Takayama、Abigail Baldridge、Sofiya Leshchenko-Yashchuk、Heather B. Miller、Yuan-Fang Wang、Andrey Y. Kovalevsky、Yashiro Koh、Irene T. Weber、Hiroaki Mitsuya
DOI:10.1039/b809178a
日期:——
Recently, we designed a series of novel HIV-1 protease inhibitors incorporating a stereochemically defined bicyclic fused cyclopentyl (Cp-THF) urethane as the high affinity P2-ligand. Inhibitor with this P2-ligand has shown very impressive potency against multi-drug-resistant clinical isolates. Based upon the -bound HIV-1 protease X-ray structure, we have now designed and synthesized a number of meso-bicyclic
最近,我们设计了一系列新颖的HIV-1蛋白酶抑制剂,它们结合了立体化学定义的双环稠合环戊基(Cp-THF)氨基甲酸酯作为高亲和力P2-配体。使用这种P2配体的抑制剂对耐多药临床分离株显示出非常出色的效能。基于结合的HIV-1蛋白酶X射线结构,我们现在设计并合成了许多中双环配体,可以想象与Cp-THF配体相似地相互作用。中相配体的设计非常吸引人,因为它们不包含任何立体中心。掺入双环1,3-二氧戊环和双环1,4-二氧六环的氨基甲酸酯的抑制剂已显示出有效的酶抑制和抗病毒活性。在该系列中,抑制剂(K(i)= 0.11 nM; IC(50)= 3.8 nM)显示出非常有效的抗病毒活性。尽管抑制剂显示出相当的酶抑制活性(K(i)= 0.18 nM),但其抗病毒活性(IC(50)= 170 nM)却比抑制剂弱得多。抑制剂对一系列与氨普瑞那韦相当的多药耐药临床分离株具有抗病毒效力。结合的HIV-1蛋白酶的